Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2015 02:32 ET | Source: Active Biotech

Active Biotech AB Interim report January - September 2015

LUND, Sweden, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Laquinimod The pivotal CONCERTO clinical Phase 3 study in relapsing remitting MS (RRMS) is proceeding according to plan and results are expected in 2017...
November 06, 2015 02:30 ET | Source: Active Biotech

Active Biotech AB Delårsrapport januari - september 2015

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod Den registreringsgrundande...
November 06, 2015 02:30 ET | Source: Active Biotech

Active Biotech AB Interim report January - September 2015

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Laquinimod The pivotal CONCERTO clinical...
October 06, 2015 08:11 ET | Source: Active Biotech

Active Biotech's partner Teva presents data on laquinimod for the treatment of multiple sclerosis at 31st ECTRIMS Congress

LUND, Sweden, Oct. 6, 2015 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ:ACTI) today announces that the collaboration partner Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present data...
October 06, 2015 08:00 ET | Source: Active Biotech

Active Biotechs partner Teva presenterar data för laquinimod mot multipel skleros på den vetenskapliga konferensen ECTRIMS

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund den 6 oktober, 2015 - Active Biotech (NASDAQ...
October 06, 2015 08:00 ET | Source: Active Biotech

Active Biotech's partner Teva presents data on laquinimod for the treatment of multiple sclerosis at 31st ECTRIMS Congress

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund, October 6, 2015 - Active Biotech (NASDAQ...
September 28, 2015 02:39 ET | Source: Active Biotech

Final results from Active Biotech's 10TASQ10 Phase 3 study of tasquinimod presented at the ECC conference

LUND, Sweden, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces, at the European Cancer Congress (ECC 2015) held in Vienna 25-29 September, the presentation of...
September 28, 2015 02:30 ET | Source: Active Biotech

Final results from Active Biotech's 10TASQ10 Phase 3 study of tasquinimod presented at the ECC conference

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund (Sweden) 28 September 2015 - Active Biotech...
September 28, 2015 02:30 ET | Source: Active Biotech

Finala resultat från Active Biotechs tasquinimod fas 3-studie 10TASQ10 presenteras på konferensen ECC

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund den 28 september 2015 - Active Biotech...
August 07, 2015 02:38 ET | Source: Active Biotech

Active Biotech AB Interim report January - June 2015

LUND, Sweden, Aug. 7, 2015 (GLOBE NEWSWIRE) -- Operations focused on the laquinimod projects and organization adjusted accordingly Laquinimod The pivotal CONCERTO clinical Phase III...